![]() ChemomAb ChemomAb is a clinical stage biopharmaceutical company which develops therapeutic antibodies for the treatment of autoimmune and inflammatory diseases. | ![]() Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. | ![]() Inozyme Inozyme is a biotechnology company that develops medicines to treat rare diseases of calcification. | ||
Founding Date | Founding Date 2010 | Founding Date 2014 | Founding Date 2016 | Founding Date 1997 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Tel Aviv-Yafo, IL HQ | Locations London, GB HQ London, GB | Locations Boston, US HQ Boston, US Boston, US | Locations Gaithersburg, US HQ |
Employees | Employees N/A | Employees 647 | Employees 653% increase | Employees 691% increase |
Valuation ($) | Valuation ($) 28.1 m | Valuation ($) 1.2 b | Valuation ($) 310 m | Valuation ($) 498.2 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $75.4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $41k (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $86.6m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit ($10.7m) (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($9m) (FY, 2025) | Net income ($287.5m) (FY, 2025) | Net income ($102m) (FY, 2024) | Net income ($88.1m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised $ 15m | Total funding raised $ 281.7m | Total funding raised $ 116m | Total funding raised $ 47.7m |

Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View company
Inozyme is a biotechnology company that develops medicines to treat rare diseases of calcification.
View company
Altimmune is a clinical-stage immunotherapeutics company.
View company